What is Mammogen?
Mammogen operates at the intersection of biotechnology and womens health, specializing in the development of non-invasive diagnostic solutions. By leveraging advanced transcriptomics and blood-based biomarkers, the company is pioneering a new class of liquid biopsy tests designed to detect breast cancer at its earliest, most treatable stages. Currently in the clinical development phase, Mammogen is actively engaged in rigorous research partnerships and clinical studies to validate its diagnostic platform. The company's market position is defined by its commitment to precision medicine, aiming to replace invasive procedures with high-sensitivity, molecular-level screening tools that offer significant improvements in patient outcomes and healthcare efficiency.
How much funding has Mammogen raised?
Mammogen has raised a total of $30M across 1 funding round:
Series A
$30M
Series A (2026): $30M, investors not publicly disclosed
Key Investors in Mammogen
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Mammogen?
With the recent influx of capital, Mammogen is poised to scale its clinical validation efforts and navigate the complex regulatory landscape required for commercialization. The strategic roadmap focuses on expanding the utility of its transcriptomic platform, potentially broadening its diagnostic scope beyond breast cancer. As the company transitions from research-heavy development to commercial readiness, the focus will shift toward establishing robust clinical evidence and forging strategic alliances with healthcare providers. This phase is critical for Mammogen as it seeks to integrate its liquid biopsy technology into mainstream clinical workflows, ultimately aiming to set a new benchmark for early-stage cancer detection and personalized therapeutic intervention.
See full Mammogen company page
